Celyad Oncology SA (CYAD.BR)
EUR 0.47
(0.65%)
EUR 0.47
(0.65%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 33 Thousand EUR | 102.29% |
| 2022 | -1.44 Million EUR | 5.26% |
| 2021 | -1.52 Million EUR | -30500.0% |
| 2020 | 5000.00 EUR | -16.67% |
| 2019 | 6000.00 EUR | -99.81% |
| 2018 | 3.11 Million EUR | 2.98% |
| 2017 | 3.02 Million EUR | -64.29% |
| 2016 | 8.47 Million EUR | 232.78% |
| 2015 | -6.37 Million EUR | -20677.42% |
| 2014 | 31 Thousand EUR | 101.28% |
| 2013 | -2.41 Million EUR | 63.57% |
| 2012 | -6.62 Million EUR | -14.87% |
| 2011 | -5.77 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 5000.00 EUR | 0.0% |
| 2023 FY | 889 Thousand EUR | 161.74% |
| 2023 Q4 | 33 Thousand EUR | 0.0% |
| 2023 Q2 | -397 Thousand EUR | 0.0% |
| 2022 FY | -1.44 Million EUR | 5.26% |
| 2022 Q4 | -469 Thousand EUR | 0.0% |
| 2022 Q2 | -971 Thousand EUR | 0.0% |
| 2022 Q1 | - EUR | 100.0% |
| 2021 Q2 | -841 Thousand EUR | 0.0% |
| 2021 Q4 | -679 Thousand EUR | 0.0% |
| 2021 FY | -1.52 Million EUR | -30500.0% |
| 2021 Q1 | - EUR | 100.0% |
| 2021 Q3 | - EUR | 100.0% |
| 2020 FY | 5000.00 EUR | -16.67% |
| 2020 Q3 | - EUR | -100.0% |
| 2020 Q4 | -937 Thousand EUR | 0.0% |
| 2020 Q2 | 5000.00 EUR | 0.0% |
| 2019 Q2 | -894.5 Thousand EUR | -59733.33% |
| 2019 FY | 6000.00 EUR | -99.81% |
| 2019 Q4 | 6000.00 EUR | 0.0% |
| 2019 Q1 | 1500.00 EUR | -99.75% |
| 2018 Q2 | 2.51 Million EUR | 223.34% |
| 2018 Q1 | 778.75 Thousand EUR | 3144.79% |
| 2018 FY | 3.11 Million EUR | 2.98% |
| 2018 Q4 | 597 Thousand EUR | 0.0% |
| 2017 Q2 | 2.97 Million EUR | 293.92% |
| 2017 FY | 3.02 Million EUR | -64.29% |
| 2017 Q4 | 24 Thousand EUR | 0.0% |
| 2017 Q1 | 756.25 Thousand EUR | -91.06% |
| 2016 Q4 | 8.45 Million EUR | 0.0% |
| 2016 FY | 8.47 Million EUR | 232.78% |
| 2016 Q2 | 14 Thousand EUR | -99.34% |
| 2016 Q1 | 2.11 Million EUR | 105775.0% |
| 2015 Q4 | 2000.00 EUR | 300.0% |
| 2015 FY | -6.37 Million EUR | -20677.42% |
| 2015 Q3 | 500.00 EUR | 0.0% |
| 2015 Q2 | 500.00 EUR | 0.0% |
| 2015 Q1 | 500.00 EUR | -98.39% |
| 2014 Q1 | 7750.00 EUR | 100.25% |
| 2014 FY | 31 Thousand EUR | 101.28% |
| 2014 Q4 | 31 Thousand EUR | 300.0% |
| 2014 Q3 | 7750.00 EUR | 0.0% |
| 2014 Q2 | 7750.00 EUR | 0.0% |
| 2013 Q3 | -603.8 Thousand EUR | 81.08% |
| 2013 Q4 | -3.15 Million EUR | -422.55% |
| 2013 FY | -2.41 Million EUR | 63.57% |
| 2013 Q1 | -603.8 Thousand EUR | -0.0% |
| 2013 Q2 | -3.19 Million EUR | -428.6% |
| 2012 Q2 | -1.65 Million EUR | 0.0% |
| 2012 FY | -6.62 Million EUR | -14.87% |
| 2012 Q1 | -1.65 Million EUR | -0.0% |
| 2012 Q3 | -1.65 Million EUR | -0.0% |
| 2012 Q4 | -603.8 Thousand EUR | 63.57% |
| 2011 Q4 | -1.65 Million EUR | -14.87% |
| 2011 Q1 | -1.44 Million EUR | -0.0% |
| 2011 Q2 | -1.44 Million EUR | 0.0% |
| 2011 Q3 | -1.44 Million EUR | -0.0% |
| 2011 FY | -5.77 Million EUR | 0.0% |
| 2010 Q4 | -1.44 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nicox S.A. | -11.5 Million EUR | 100.287% |
| European Medical Solutions | 13.51 Million EUR | 99.756% |
| FERMENTALG | 535 Thousand EUR | 93.832% |
| argenx SE | 925.49 Million EUR | 99.996% |
| BioSenic S.A. | 543 Thousand EUR | 93.923% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 98.345% |
| Onward Medical N.V. | -14.81 Million EUR | 100.223% |
| Oxurion NV | 104 Thousand EUR | 68.269% |
| PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 97.511% |
| Financière de Tubize SA | -2.02 Million EUR | 101.626% |
| UCB SA | 3.34 Billion EUR | 99.999% |